Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 28, 2023 -- There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) in patients with type 2 diabetes, according to a review published online Sept. 21 in the Journal of the Royal Society of Medicine.
Setor K. Kunutsor, M.D., Ph.D., from University of Leicester in the United Kingdom, and colleagues conducted a systematic literature review and meta-analysis to compare racial/ethnic as well as regional pattern effects for SGLT2is and GLP1-RAs on cardiovascular disease (CVD) and renal outcomes in patients with type 2 diabetes.
Based on 14 included trials, the researchers found that the risk for major adverse cardiovascular events (MACE) varied with SGLT2is by race (White: hazard ratio [HR], 0.92; Asian: HR, 0.69; Hispanic/Latino: HR, 0.70) versus placebo. Similar results were seen for GLP1-RAs versus placebo (HRs, 0.88, 0.76, and 0.82, respectively). For other cardiorenal outcomes, SGLT2is reduced the risk in White and Asian populations, except for heart failure hospitalizations in Asians. There were no effects found in Black populations except for a reduced risk for heart failure hospitalizations by SGLT2i. The risk for composite CVD death/heart failure hospitalization was reduced with SGLT2-Is in North America and Europe, while GLP1-RAs cut the risk for MACE in Europe. Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) certainty of evidence ranged from moderate to high.
"Whether the differences are due to issues with underrepresentation of Black populations and low statistical power or racial/ethnic variations in the pharmacokinetics, pharmacodynamics, and safety of SGLT2-Is and GLP1-RAs needs further investigation," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Large Language Models May Aid Emergency Department Triage
TUESDAY, May 14, 2024 -- Large language models (LLMs) could enhance emergency department triage workflows, according to a study published online May 7 in JAMA Network...
Neighborhood Inequity Tied to More People Living With Vision Difficulty, Blindness
TUESDAY, May 14, 2024 -- Residential measures of inequity are associated with a greater number of individuals living with vision difficulty and blindness (VDB), according to a...
Elite Running Tied to Longer Life Expectancy
TUESDAY, May 14, 2024 -- Sub-four-minute mile runners have greater longevity than the general population, with results dating back as far as the 1950s, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.